Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Rinsho Ketsueki ; 65(5): 335-339, 2024.
Article in Japanese | MEDLINE | ID: mdl-38825510

ABSTRACT

A 69-year-old woman was previously treated with antibiotics for suspected pyelonephritis due to fever but showed limited improvement. Contrast-enhanced CT revealed heterogeneous areas of decreased contrast enhancement in both kidneys, along with an elevated soluble level of the IL-2 receptor (5,090 U/ml), and thus the patient was referred to our department for further evaluation. A percutaneous renal biopsy performed due to suspected malignant lymphoma confirmed lymphoma cell infiltration into the renal interstitium. Immunohistochemical staining was positive for MYC/BCL2/BCL6, leading to the diagnosis of stage IVB primary renal triple expressor diffuse large B cell lymphoma (DLBCL). Due to acute kidney injury, continuous hemodiafiltration (CHDF) was initiated, followed by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. The patient's renal function improved rapidly, and complete response was achieved after six cycles of R-CHOP. Although DLBCL is a common lymphoma, the primary renal subtype is extremely rare and poses both diagnostic and therapeutic challenges. This case highlights the potential clinical implications of combining CHDF with chemotherapy to achieve complete response despite an initial poor prognosis based on the patient's overall clinical condition and pathology.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Doxorubicin , Kidney Neoplasms , Lymphoma, Large B-Cell, Diffuse , Prednisone , Vincristine , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/therapy , Lymphoma, Large B-Cell, Diffuse/pathology , Female , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Doxorubicin/administration & dosage , Vincristine/administration & dosage , Vincristine/therapeutic use , Kidney Neoplasms/drug therapy , Kidney Neoplasms/pathology , Kidney Neoplasms/therapy , Prednisone/administration & dosage , Prednisone/therapeutic use , Cyclophosphamide/administration & dosage , Rituximab/administration & dosage , Rituximab/therapeutic use , Renal Dialysis , Treatment Outcome , Hemodiafiltration
4.
J Infect Chemother ; 29(8): 796-799, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37075980

ABSTRACT

We herein report a 76-year-old man with acquired hemophilia A (AHA) who developed gallbladder rupture due to Ceftriaxone (CTRX)-associated pseudolithiasis. The patient was admitted for an examination of systemic subcutaneous bleeding. A blood test showed a prolonged activated partial thromboplastin time and sequentially revealed low factor VIII activity (<1%) and a high factor VIII inhibitor level of 143 BU/mL. The patient was thus diagnosed with AHA. After admission, he developed a high-grade fever and was administered intravenous CTRX, considering the possibility of psoas abscess or cellulitis. Although his high-grade fever was improved, computed tomography incidentally showed a high-density lesion in the gallbladder, suggestive of CTRX-associated pseudolithiasis without clinical symptoms. Despite cessation of CTRX, the pseudolithiasis never disappeared, and the patient suddenly died after rapid progression of abdominal bloating. An autopsy revealed that the gallbladder was severely swollen and had ruptured with hemorrhaging because of hemorrhagic cholecystitis, caused by CTRX-associated pseudolithiasis with AHA. Our case demonstrated that CTRX-associated pseudocholelithiasis can unexpectedly induce gallbladder hemorrhaging and rupture in a patient with a bleeding diathesis, including AHA. CTRX-associated pseudocholelithiasis can cause a fatal outcome in patients with a bleeding disorder, even if CTRX is ceased as soon as pseudocholelithiasis is detected.


Subject(s)
Ceftriaxone , Hemophilia A , Male , Humans , Aged , Ceftriaxone/adverse effects , Factor VIII , Anti-Bacterial Agents/adverse effects , Gallbladder , Hemophilia A/complications , Hemophilia A/chemically induced , Hemophilia A/drug therapy
5.
Transpl Immunol ; 77: 101792, 2023 04.
Article in English | MEDLINE | ID: mdl-36682572

ABSTRACT

Donor lymphocyte infusion (DLI) is a curable treatment option, inducing a graft-versus-tumor effect in patients with relapsed hematological malignancies after allogeneic hematopoietic cell transplantation (allo-HCT). However, not only graft-versus-host disease but also pulmonary complications are problematic adverse events after DLI. Although viral infections can be associated with pulmonary complications after DLI, the mechanism underlying these complications remains unclear. Detecting the causative virus infections after pulmonary complications following DLI is challenging, as invasive examinations, such as bronchoalveolar lavage and lung biopsies, are necessary. Family Picornaviridae, including Human-Rhinovirus (HRV) and Enterovirus (EnV), can induce fatal lower respiratory tract infection (LRTI) in recipients who undergo allo-HCT, which can be underdiagnosed. We encountered a 62-year-old man with relapsed myelodysplastic syndrome 20 days after a second HLA-haplo-identical allo-HCT and 4 DLI procedures who was later found to have HRV and EnV LRTI by postmortem electron microscopy. Despite high-dose immunosuppression, severe hypoxemia did not improve, and he succumbed to respiratory failure. Immunosuppressive therapy for idiopathic pneumonia syndrome after allo-HCT may be effective, but its efficacy for acute respiratory failure after DLI is controversial. Our case indicated that the control of viral replication should be prioritized over that of inflammation in HRV and EnV LRTI after DLI.


Subject(s)
Enterovirus , Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Myelodysplastic Syndromes , Respiratory Tract Infections , Male , Humans , Middle Aged , Rhinovirus , Transplantation, Homologous , Neoplasm Recurrence, Local/etiology , Myelodysplastic Syndromes/therapy , Myelodysplastic Syndromes/etiology , Respiratory Tract Infections/etiology , Graft vs Host Disease/pathology , Lymphocytes/pathology , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/methods , Lymphocyte Transfusion/methods
6.
Langmuir ; 33(41): 11040-11046, 2017 10 17.
Article in English | MEDLINE | ID: mdl-28949148

ABSTRACT

The spontaneous spreading of thin liquid films over substrate surfaces is attracting much attention due to its broad applications. Under particular conditions, surfactants deposited on substrates exhibit unstable spreading. In spite of the large effects of the stability of the spreading on the accuracy and efficiency of industrial processes that use the spreading, understanding how the stability of the spreading process is governed by the physical and chemical properties of the system is still little known. Recently, ionic liquids have been characterized as a new kind of surfactant due to their special properties. Here, we investigate the stability of the spreading of deposited imidazolium-based ionic liquids on an aqueous substrate. We focus mainly on the effects that the water solubility of the ionic liquids has on the stability. Hydrophobic ionic liquids exhibit spreading that has a highly periodic and petal-like unstable spreading front, whereas hydrophilic ionic liquids spread without such a regular spreading front and their spreading area shrinks after reaching its maximum. We propose a model for the generation of unstable spreading of hydrophobic ionic liquids, i.e., the unstable spreading front is created by the penetration of oncoming water in front of the spreading tip into the more viscous spreading ionic liquid layer, like the viscous fingering that occurs in a Hele-Shaw cell. However, the direction of the penetration is the opposite of the direction that the interface moves (the spreading direction), which is contrary to that in viscous fingering.

SELECTION OF CITATIONS
SEARCH DETAIL
...